X-37 is a pharmaceutical discovery and development company that uses advanced artificial intelligence technology from Atomwise to screen vast libraries of chemical compounds against high-value pharmaceutical targets. It develops novel drug candidates under an LLC structure that permits the sale or partnership of individual development programs. Its pipeline includes programs targeting ZAP-70 for autoimmune disease, PIM3 and SHP2 for cancer, and Factor XIIa for anticoagulation. Led by CEO David Collier, M.D., and a team from Velocity Pharmaceutical Development, X-37 intends to expand the number of drug development programs and advance identified leads through laboratory and preclinical testing. The company closed a $14.5M Series A financing to fund these efforts and aims to begin human clinical trials by 2022.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2019